Gilead has grown to become a leader in the fight against HIV and has announced efforts to improve access to a new, highly ...
They put a lot of effort and money into research and development, especially for antiviral drugs for HIV ... access to lenacapavir for pre-exposure prophylaxis (PrEP) if approved. Analysts have a ...
The next referendum on Gilead Sciences’ oft-criticized oncology business is approaching. Circle Nov. 5 on your calendars.
Both the CDC and the FDA warn against treating this common childhood condition on your own with non-prescription treatments. See what they recommend.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback